Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2125]

Non-TBI conditioning achieves positive results in MRD-negative CAYA B-ALL...

Prof Hisham Abdel-Azim - Loma Linda University, Loma Linda, USA

Non-TBI conditioning achieves positive results in MRD-negative CAYA B-ALL undergoing allogeneic HCT ( Prof Hisham Abdel-Azim - Loma Linda University, Loma Linda, USA )

Comment: Pirtobrutinib improves PFS in treatment-naïve CLL/SLL compared to...

Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA

Comment: Pirtobrutinib improves PFS in treatment-naïve CLL/SLL compared to bendamustine/rituximab ( Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA )

Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy...

Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA

Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy in high-risk mantle cell lymphoma ( Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA )

Ropeginterferon alfa-2b is evaluated as a disease-modifying option in essential...

Prof Jean-Jacques Kiladjian - Hôpital Saint-Louis, Paris, France

Ropeginterferon alfa-2b is evaluated as a disease-modifying option in essential thrombocythemia ( Prof Jean-Jacques Kiladjian - Hôpital Saint-Louis, Paris, France )

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL

Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL ( Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany )

Off-the-shelf in vivo CAR-T therapy KLN-1010 shows early MRD-negative responses...

Prof Joy Ho - Royal Prince Alfred Hospital, Sydney, Australia

$Off-the-shelf in vivo CAR-T therapy KLN-1010 shows early MRD-negative responses in relapsed/refractory multiple myeloma ( Prof Joy Ho - Royal Prince Alfred Hospital, Sydney, Australia )$

MRD validated as a surrogate endpoint for survival in AML

Dr Jesse Tettero - The Hourigan Lab, Washington, D.C., USA

MRD validated as a surrogate endpoint for survival in AML ( Dr Jesse Tettero - The Hourigan Lab, Washington, D.C., USA )

Anitocabtagene autoleucel achieves deep and durable responses in relapsed...

Dr Krina Patel - MD Anderson Cancer Center, Houston, USA

$Anitocabtagene autoleucel achieves deep and durable responses in relapsed/refractory multiple myelomas ( Dr Krina Patel - MD Anderson Cancer Center, Houston, USA )$

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor...

Dr Keith McCrae - Cleveland Clinic, Cleveland, USA

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis ( Dr Keith McCrae - Cleveland Clinic, Cleveland, USA )

Exploring genomic insights in acute lymphoblastic leukaemia treatment

Prof Charles Mullighan - St. Jude Children's Research Hospital, Memphis, USA

Exploring genomic insights in acute lymphoblastic leukaemia treatment ( Prof Charles Mullighan - St. Jude Children's Research Hospital, Memphis, USA )

Talquetamab plus teclistamab shows promise in true extramedullary multiple...

Dr Shahzad Raza - Cleveland Clinic, Cleveland, USA

Talquetamab plus teclistamab shows promise in true extramedullary multiple myeloma ( Dr Shahzad Raza - Cleveland Clinic, Cleveland, USA )

AI and pathology reveal higher late recurrence risk in invasive lobular breast...

Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer ( Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia )

More from ecancer